Genetic Technologies
- Short interest
- 0.00%
- 0.00 pp 30d
- as of 23 Mar 2021
- Reported shorts
- 355K
- Shares on issue
- 9.017B
Genetic Technologies (GTG) Short Interest
Genetic Technologies (ASX:GTG) had 0.00% of shares reported as short positions as of 23 Mar 2021, representing 355,000 shares. Genetic Technologies operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Genetic Technologies
GTG is a global leader in guideline driven genomics based tests in health, wellness and serious disease with its patented geneType polygenic based risk tests and EasyDNA brands. Our portfolio also includes pharmacogenomics, Non-Invasive Prenatal Testi
Company profile →Genetic Technologies (ASX:GTG) has 0.00% of its shares on issue reported as short positions as of 23 Mar 2021, or about 355,000 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 4.62% in January 2016. GTG is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads GTG today
- Zanger BreakoutWatchScore 26rank 808 of 1942
- CAN SLIMWatchScore 20rank 676 of 1541
- Minervini Trend TemplateWatchScore 15rank 1111 of 1716
- Crowded-Short BreakoutWatchScore 9rank 1131 of 1500
- Quality compoundersWatchScore 9rank 1399 of 1669
Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
GTG fundamentals
In the year to 30 Jun 2026, Genetic Technologies (ASX:GTG) recorded revenue of A$0 and a net loss after tax of A$428.6K. A year earlier it recorded revenue of A$0 and a net loss after tax of A$1.5M. Figures are in AUD, the company's reporting currency; source: ASX (Markit) and Yahoo Finance, as at 14 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest GTG news
All news- Shizim VS Ltd Acquires 11.57% Stake in Identifai Genetics Limited, Files Substantial Holder Notice
kalkine · 13 Oct 2026
- Identifai Genetics lists at a premium after $10m IPO to take AI prenatal blood test to US
businessnews · 13 Oct 2026
- Health Check: No ‘Flop-us’ fears as Identifai Genetics lists on a firm note
stockhead · 13 Oct 2026
Company details
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss GTG
Start a research thread or post the first pulse update